Page 9 - Shivam Tyagi

Stocks to watch on May 8: IRB Infra, IGL, Sonata Software, IDBI Bank, SJVN

Stocks to watch on May 8, 2024: IRB Infrastructure Developers on Tuesday reported a 45 per cent rise in consolidated net profit to Rs 188.87 crore for the March 2024 quarter

Dr Reddy's, Pidilite, UB, HZL, Voltas among six stocks to watch today

United Breweries announced a more than five-fold increase in net profit to Rs 80.15 crore for the January-March period of 2023-24 compared to the same period last year

Mid, SmallCap indices slip up to 3% on May 7; analysts cite rich valuations

Among midcaps Lupin fell 6.58 per cent at Rs 1569 as the pharma major missed street expectations in its January-March quarter earnings

L&T Q4 preview: Company may see 22% YoY jump in PAT; check key monitorables

On a quarter on quarter (Q-o-Q) basis, the company may see a sequential surge of 15-20 per cent in revenue in the January-March of FY24

Stocks to watch, May 7: Wipro, Bajaj Finserv, Zee Media, Muthoot Microfin

Stocks to Watch on May 7, 2024: Wipro partnered with Microsoft to introduce a suite of Generative AI-powered virtual assistants for financial services

IndiGo, Lupin, DCM Shriram and Gujarat Gas among six stocks to watch today

Stocks to Watch on May 7: Lupin Limited posted a 52 per cent year-on-year (Y-o-Y) surge in its consolidated net profit, reaching Rs 359.43 crore

Godrej Properties zooms 11% on strong profits; analysts bullish for FY25

Godrej Properties posted a 14 per cent year-on-year (YoY) increase in its consolidated net profit, reaching Rs 471 crore for the quarter ending March 2024

Dr Reddy's Q4 Preview: Here's what key brokerages expect from its results

Indian pharmaceutical giant Dr Reddy's Laboratories is set to witness a single to double digit growth in sales on a year-on-year (Y-o-Y) basis for the fourth quarter of financial year 2023-24 (Q4FY23)

Indegene IPO opens today, May 06. Planning to subscribe? What analysts say

Indegene provides services for the life sciences industry. They assist with drug development, clinical trials, regulatory submissions, pharmacovigilance, complaints management, and sales and marketing

Q4 Results Preview: Lupin may see strong topline, bottomline growth

Indian pharmaceutical major Lupin is set to witness a strong financial earnings on a year-on-year (Y-o-Y) basis for the fourth quarter of the financial year 2023-24 (Q4FY23)

Stocks to watch on May 6: Tata Power, Sun Pharma, Zydus Life, Nerolac

Stocks to watch, Monday, May 6: Jammu and Kashmir Bank on Saturday reported its highest-ever annual profit at Rs 1,767 crore for 2023-24

Kotak Mahindra Bank, Paytm, Mahindra Fin, among six stocks to watch today

Indian equity markets are poised to regain some lost ground on Monday after Friday's significant downturn. As of 7:35 AM, the GIFT Nifty was trading at 22,688, marking an increase of 112 points

Analysts recommend buying these 3 finance stocks, see up to 25% upside

REC Limited and Power Finance Corporation have soared up to 10 per cent each in the last 30 days on the NSE

Lowering prices to weigh down earnings of Indian API players in near term

According to the brokerage, prices of APIs such as Paracetamol, Azithromycin, Montelukast, and Meropenem, have all declined in the range of 10-30 per cent over the last one year

Wipro Q4 Preview: profits may decline 8-10%, revenues to dip 4-5% YoY

According to brokerage estimates, Wipro is likely to report a net profit in the range of Rs 2,778 crore to Rs 2,829 crore for the fourth quarter, down 8-10 per cent year on year (YoY)

Expensive valuations leave limited upside in Bajaj Auto, caution analysts

Despite strong earnings, analysts warned investors on future growth trends as most positives of the company are priced in and the stock is currently trading at high valuations

Analysts recommend buying these Oil & Gas stocks; see upside of up to 21%

Shares of oil marketing companies such as HPCL, BPCL and IOCL have corrected 9-18 per cent since mid-Feb as the gross marketing margins on petrol and diesel have declined

Infosys Q4FY24 result preview: Low single-digit topline growth expected

According to brokerages, Infosys is likely to report a revenue increase of 2-4 per cent year-on-year between Rs 38,945 crore to Rs 38,432 crore

Goldman Sachs bullish on Indian CDMO sector, recommends buying these stocks

Goldman Sachs attributes India's underpenetrated CDMO and CRO market to smaller capacities, lack of Innovation with little collaboration between Industry and academia

Q4 Preview: TCS to lead IT pack; may see upper single digit rise in profit

Reversal of furloughs and incremental contribution from the BSNL deal and other deals will fuel the revenues